Shares of Accelerate Diagnostics Inc (NASDAQ:AXDX) have been given a consensus recommendation of “Hold” by the six ratings firms that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and two have given a buy recommendation to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $21.00.
A number of research firms recently weighed in on AXDX. Zacks Investment Research lowered shares of Accelerate Diagnostics from a “buy” rating to a “hold” rating in a research report on Tuesday, December 4th. BidaskClub raised shares of Accelerate Diagnostics from a “strong sell” rating to a “sell” rating in a research report on Saturday, January 5th.
Shares of AXDX traded up $0.26 during trading hours on Wednesday, reaching $19.89. 5,037 shares of the stock traded hands, compared to its average volume of 232,100. The company has a debt-to-equity ratio of 2.09, a current ratio of 22.88 and a quick ratio of 21.89. Accelerate Diagnostics has a 52 week low of $10.23 and a 52 week high of $25.35. The firm has a market capitalization of $1.08 billion, a P/E ratio of -12.38 and a beta of 3.18.
Accelerate Diagnostics (NASDAQ:AXDX) last released its quarterly earnings results on Tuesday, February 19th. The medical research company reported ($0.41) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.41). Accelerate Diagnostics had a negative net margin of 1,564.01% and a negative return on equity of 105.12%. The company had revenue of $1.80 million for the quarter, compared to analyst estimates of $1.83 million. On average, equities research analysts expect that Accelerate Diagnostics will post -1.76 earnings per share for the current year.
A number of hedge funds have recently made changes to their positions in the business. Credit Suisse AG raised its position in Accelerate Diagnostics by 5.0% in the third quarter. Credit Suisse AG now owns 3,653,892 shares of the medical research company’s stock worth $83,856,000 after acquiring an additional 173,289 shares during the period. BlackRock Inc. raised its position in Accelerate Diagnostics by 2.0% in the third quarter. BlackRock Inc. now owns 1,785,849 shares of the medical research company’s stock worth $40,983,000 after acquiring an additional 34,958 shares during the period. Vanguard Group Inc increased its stake in shares of Accelerate Diagnostics by 0.8% in the third quarter. Vanguard Group Inc now owns 1,291,417 shares of the medical research company’s stock worth $29,638,000 after purchasing an additional 10,601 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Accelerate Diagnostics by 0.8% in the third quarter. Vanguard Group Inc. now owns 1,291,417 shares of the medical research company’s stock worth $29,638,000 after purchasing an additional 10,601 shares in the last quarter. Finally, Amundi Pioneer Asset Management Inc. increased its stake in shares of Accelerate Diagnostics by 33.0% in the fourth quarter. Amundi Pioneer Asset Management Inc. now owns 991,090 shares of the medical research company’s stock worth $11,397,000 after purchasing an additional 246,000 shares in the last quarter. 50.59% of the stock is currently owned by institutional investors and hedge funds.
Accelerate Diagnostics Company Profile
Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast.
Featured Story: How to identify percentage decliners
Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.